News Releases
This section contains information and press releases about Boston Scientific. Press releases are listed in chronological order and archived by year. Information should be considered accurate as of the date prepared. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Boston Scientific is not obligated to update the press releases and information contained in this section of the website.
Click here to access archived Guidant press releases.
Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005 / 2004
2008 Archives
Dec 18, 2008 Boston Scientific Corporation today announced enrollment of the first patient... |
|
Dec 15, 2008 First low-profile, pre-mounted stent approved specifically for use in renal arteries Boston Scientific Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved the Express® SD Renal Monorail®... |
|
Nov 24, 2008 Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray Health Care Conference, which is being held December 2 -... |
|
Nov 10, 2008 New design provides more options for treating patients with complex lesions Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the U.S. Food and Drug Administration to market its... |
|
Oct 29, 2008 Boston Scientific Corporation (NYSE: BSX) today welcomed passage of legislation to help active members of the U.S. armed forces and service... |
|
Oct 27, 2008 Confirms clinical value and cost-effectiveness of spinal cord stimulation Boston Scientific Corporation (NYSE: BSX) today welcomed an announcement by the U.K.'s National Institute for Health and Clinical Excellence (NICE)... |
|
Oct 23, 2008 Leading carotid stent in Europe and other international markets now available in the United States Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved its Carotid WALLSTENT®... |
|
Oct 21, 2008 Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2008, as well as guidance for... |
|
Oct 15, 2008 Landmark trial provides new insight for physicians Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of the HORIZONS AMI trial. The HORIZONS AMI... |
|
Oct 15, 2008 Boston Scientific Corporation (NYSE: BSX) today announced positive one-year results from the Intercontinental and European launch... |
|
Oct 14, 2008 New SYNTAX Score shows similar safety and efficacy outcomes for two thirds of study's patients Boston Scientific Corporation (NYSE: BSX) today announced 12-month left main and three-vessel disease subset data from its landmark... |
|
Oct 14, 2008 Company moves up Q3 earnings release date Boston Scientific Corporation (NYSE: BSX) today provided the following comments reinforcing the strength of its balance sheet: The volatility of... |
|
Oct 14, 2008 TAXUS® Atom™ in more than 500 accounts Company opening new PROMUS™ accounts Boston Scientific Corporation (NYSE: BSX) today announced estimated U.S. market shares for September for its two drug-eluting stents (DES), based... |
|
Oct 13, 2008 Joint efforts will focus on intravascular ultrasound (IVUS) GE Healthcare (NYSE: GE) and intravascular ultrasound (IVUS) market leader Boston Scientific Corporation (NYSE: BSX) today... |
|
Oct 13, 2008 Thursday and Friday of last week saw continued heavy trading in Boston Scientific's (NYSE: BSX) stock. As anticipated in the Company's October 9th... |
|
Oct 12, 2008 Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of nearly 7,500 patients from its TAXUS ARRIVE 1... |
|
Oct 12, 2008 New coronary stent features thin struts designed for more uniform drug delivery Boston Scientific Corporation (NYSE: BSX) today announced comprehensive data from the TAXUS ATLAS clinical program, a series of... |
|
Oct 10, 2008 Boston Scientific Corporation (NYSE: BSX) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its... |
|
Oct 10, 2008 Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Cardiovascular... |
|
Oct 9, 2008 Yesterday saw heavy trading in Boston Scientific's (NYSE: BSX) stock, with approximately 38 million shares traded. This trading included involuntary... |
|
Oct 8, 2008 Boston Scientific (NYSE: BSX) announced today it expects to record the following adjustments to its third quarter results, which it plans to report... |
|
Oct 8, 2008 PERSEUS clinical program to evaluate TAXUS® Element™ Platinum Chromium Stent Boston Scientific Corporation (NYSE: BSX) today announced that it has completed enrollment in the PERSEUS trial, designed to evaluate the Company's... |
|
Oct 1, 2008 Boston Scientific Corporation (NYSE: BSX) announced today that the United States District Court in Delaware has entered judgment against the Company... |
|
Sep 25, 2008 Company also announces FDA approval of TAXUS® Express2™ Stent System for treatment of in-stent restenosis Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market... |
|
Sep 19, 2008 Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the UBS Global Life Sciences Conference, which is being held September 22... |
|
1-25 26-50 51-75 76-92 | |